Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00029224
Status:
COMPLETED
Last Update Posted:
2012-02-01
First Post:
2002-01-09
Brief Title:
Treatment With Zoledronic Acid in Patients With Breast Cancer Multiple Myeloma and Prostate Cancer With Cancer Related Bone Lesions
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Prospective Multicenter Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer Multiple Myeloma and Prostate Cancer Patients With Cancer-related Bone Lesions
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with bone metastases or bone lesions caused by breast cancer multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion Pain will be evaluated as well as time in chair quality of life and safety of Zometa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None